MultiCell Technologies, Inc.  

(Public, OTCMKTS:MCET)   Watch this stock  
Find more results for Gerald
0.00000 (0.00%)
May 24 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range     -
52 week 0.00 - 0.00
Open     -
Vol / Avg. 0.00/900,743.00
Mkt cap 1.00M
P/E     -
Div/yield     -
EPS 0.00
Shares 5.00B
Beta     -
Inst. own 0%

Key stats and ratios

Q3 (Aug '15) 2014
Net profit margin -88.31% -1072.24%
Operating margin -90.85% -1035.10%
EBITD margin - -1465.53%
Return on average assets -192.51% -346.42%
Return on average equity - -
Employees 2 -
CDP Score - -


68 Cumberland St Ste 301
WOONSOCKET, RI 02895-3332
United States - Map
+1-401-7620045 (Phone)
+1-401-7620098 (Fax)

Website links


MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company. The Company and its subsidiaries are developing therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer and interventional cardiology, and peripheral vessel applications. The Company's portfolio of lead drug candidates is in various stages of discovery optimization, and preclinical and clinical development, and includes MCT-125, MCT-465, MCT-475 and MCT-485. MCT-125 is a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue. MCT-465 is a preclinical synthetic double-stranded ribonucleic acid (dsRNA) therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers. MCT-475 is a discovery-stage antibody therapeutic candidate used in combination with dsRNA for the treatment of solid tumor cancers. MCT-485 is a discovery-stage dsRNA therapeutic candidate for the treatment of certain cancers.

Officers and directors

W. Gerald Gerald Newmin Chairman of the Board, President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary
Age: 77
Stephen Chang Ph.D. Director
Age: 59
Grant G. Miller Director
Age: 59
Thomas A. Page Ph.D. Independent Director
Age: 81
Edward Sigmond Independent Director
Age: 54